Product namebpV(HOpic), PTP and PTEN inhibitor
DescriptionPTP and PTEN inhibitor
Biological descriptionInhibits PTP (IC50 = 4-25 µM) and PTEN (IC50 = 14 nM). Insulin mimetic. Enhances PI3K/Akt signaling and possibly prevents myocardium from ischemia-reperfusion injury. Active in vitro.
See similar compound
This product is not stable in water; immediately upon dissolution decomposition starts to occur. Decomposition in dry DMSO has also been observed but at a slower rate.
Chemical nameDipotassium bisperoxo(5-hydroxypyridine-2-carboxyl)oxovanadate (V)
Storage instructionsStore at -20°C. It is important to note that this product is reported to be light sensitive. Store In the Dark. Store under desiccating conditions.
Solubility overviewSoluble in DMSO
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
This product has been referenced in:
- Dimchev GA et al. Phospho-tyrosine phosphatase inhibitor Bpv(Hopic) enhances C2C12 myoblast migration in vitro. Requirement of PI3K/AKT and MAPK/ERK pathways. J Muscle Res Cell Motil 34:125-36 (2013). Read more (PubMed: 23553034) »
- Keyes KT et al. Pharmacological inhibition of PTEN limits myocardial infarct size and improves left ventricular function postinfarction. Am J Physiol Heart Circ Physiol 298:H1198-208 (2010). Read more (PubMed: 20097771) »
- Schmid AC et al. Bisperoxovanadium compounds are potent PTEN inhibitors. FEBS Lett 566:35-8 (2004). Read more (PubMed: 15147864) »